ÂÜÀòÂÒÂ×

Mr. Tighe joined TCR² in 2019 as Vice President of Research. He offers over 25 years of experience in early clinical development and IND preparation while at large pharmaceuticals and biotechnology companies. Previously, he served as Vice President of Translational Immunology and Immunopharmacology at Compass Therapeutics, where he led the discovery and IND approval of CTX-471, a CD137 agonist antibody, and built the cellular immunology and autoimmunity, research teams. Prior to Compass, he held several positions of increasing responsibility at EMD Serono, where he was a major contributor to the success of three INDs including the NHS-IL12 immunocytokine, the now approved anti-PD-L1 antibody avelumab (Bavencio™) and M7824, an anti-PD-L1/TGFβ-trap molecule. Earlier in his career, Robert served in various research roles at EMD Lexigen Research Center, ArQule, The Jackson Laboratory, Massachusetts Institute of Technology, Genetix Pharmaceuticals (now bluebird bio), and the Whitehead Institute for Biomedical Research. Robert focused on Biology and Chemistry at Salem State College.